Cases of major eye disease projected to increase among diabetics
King Pharmaceuticals, Inc. and Alpharma Inc. have announced that the two companies have signed a definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity value of approximately $1.6 billion. The Boards of Directors of
Full Post: King Pharmaceuticals and Alpharma sign definitive merger agreement
Based on projected increases in the prevalence of diabetes, the number of people with diabetes-related retinal disease, with glaucoma and with cataracts is estimated to increase significantly by 2050, according to a report in the December issue of Archives of Ophthalmology.
Diabetic retinopathy (damage to the small blood vessels in the retina) is the leading cause of blindness among American working-age adults with approximately $500 million spent on direct medical costs for diabetic retinopathy in 2004, according to background information in the article. “People with diabetes mellitus also have a higher prevalence of other eye diseases, such as cataracts and glaucoma, than the general population,” the authors write. “Vision loss related to eye disease among people with diabetes is an important disability that threatens independence and can lead to depression, reduced mobility and reduced quality of life.”
Jinan B. Saaddine, M.D., M.P.H., of the Centers for Disease Control and Prevention, Atlanta, and colleagues used published data from the 2004 National Health Interview Survey and the U.S. Census Bureau to estimate the number, age, sex and race/ethnicity of Americans with diabetes that will have the following eye conditions in the year 2050: diabetic retinopathy, vision threatening diabetic retinopathy, glaucoma and cataracts.
U.S. Census projections suggest that the total U.S. population will reach 402 million in 2050. It is expected that there will be 213 million non-Hispanic whites, 53 million blacks, 98 million Hispanics and 38 million people of other races. Based on these data and the projected increase in diabetes prevalence, the authors estimate that from 2005 to 2050 diabetic retinopathy cases will increase from 5.5 million to 16 million; vision threatening diabetic retinopathy cases will increase from 1.2 million to 3.4 million; increases in diabetic retinopathy and vision threatening diabetic retinopathy among Americans age 65 or older will be more prominent (rising from 2.5 million to 9.9 million for diabetic retinopathy and from 0.5 million to 1.9 million for vision threatening diabetic retinopathy); cataract cases among whites and blacks age 40 or older with diabetes will likely rise 235 percent; cataract cases among people with diabetes age 75 or older will increase 637 percent for black women and 677 percent for black men; and glaucoma cases among Hispanics age 65 or older with diabetes will increase 12-fold.
“In summary, our projections have shown higher numbers than previously estimated for diabetic retinopathy, vision threatening diabetic retinopathy, cataracts and glaucoma among Americans with diabetes,” they conclude. “Efforts to prevent diabetes and to optimally manage diabetes and its complications are needed.”
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly
Full Post: Protease inhibitor found to aid diabetic retinopathy treatment
A new study published in Value in Health estimates the extent of hospital admissions for individuals with diabetes and its economic burden in the U.S. The results show that, during 2005, Americans with diabetes had 3.5 times more hospital admissions than those without diabetes. Though only 7 percent of the U.S. population has diabetes, in
Full Post: Economic burden of diabetes on U.S healthcare system
It is estimated that more than 1 billion individuals worldwide in 2005 had presbyopia, or age-related difficulty in seeing objects nearby, with an estimated 410 million with the condition unable to perform tasks requiring near vision, according to a report in the December issue of Archives of Ophthalmology. Presbyopia occurs with age, as the eye’s
Full Post: Presbyopia may affect more than 1 billion worldwide
More than 20 million Americans are living with diabetes, and that number is expected to increase by more than 5 million by 2010. One complication related to diabetes, Diabetic Peripheral Neuropathy, (DM+PN), can cause individuals to develop foot ulcers and, in extreme cases, amputation might be necessary. Previously, doctors and scientists have recommended that individuals
Full Post: Diabetics with previous foot ulcers may be able to participate in walking program
Household budget cutbacks are becoming commonplace as most Americans struggle to make ends meet, but experts warn that health care needs should not be among the forfeited services. Recent research indicates that more than 20 percent of people have cut back on medical visits to save money and The Vision Council warns that this cost-saving
Full Post: Household budget cutbacks in health care could have serious consequences